Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) has developed a new autoinjector platform for liquid medications with volumes ranging from 1.5 to 5.5 ml. The YpsoMate 5.5 is the latest addition to the growing YpsoMate family of devices and is based on the established technology of the YpsoMate 2.25 Pro. YpsoMate 5.5 enables the self-administration of larger volume medications for treating cancer, rare and autoimmune diseases.

Topics:
Innovation & Digital Health

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) and Sidekick Health today announced a collaboration to extend Ypsomed’s device and SmartServices offering by implementing a self-injection module in Sidekick’s proven digital therapeutics solution. The combination of Ypsomed’s devices with Sidekick’s digital health behavioural economics and gamification expertise will form a unique solution delivering an engaging and personalized patient experience to people with chronic conditions, as well as a turn-key, best-in-class digital therapy management system to pharmaceutical customers.

Topics:
Innovation & Digital Health

Press Releases Ypsomed Group

Burgdorf – Ypsomed launches bolus delivery from the smartphone on the mylife YpsoPump via the mylife App. This new feature enables mylife YpsoPump users to deliver the bolus insulin conveniently and discreetly via their personal smartphone, without having to interact with the pump itself. Following the early summer launch of automated insulin delivery (AID) via the mylife CamAPS FX App, Ypsomed now offers an additional option for discreet remote bolus delivery to all users. People with diabetes now have the freedom to choose their preferred therapy solution.

Topics:
Innovation & Digital Health

Press Releases Ypsomed Group

Burgdorf – Ypsomed's Annual General Meeting on 29 June 2022 approved all the proposals of the Board of Directors. It elected Gilbert Achermann as the new Chairman of the Board of Directors and Simon Michel as a new member of the Board of Directors. The founder and long-standing Chairman Dr. h.c. Willy Michel was given a ceremonial farewell.

Topics:
Management

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) has completed the capital increase in the full amount of one million new shares very successfully. The subscription and placement price was set at CHF 122.50 after the expiry of the subscription and placement period, which ended on 23 June 2022 at 12:00 CEST. The issue price corresponds to the volume-weighted average price from 21 to 23 June 2022, until 12:00 noon, with a discount of 2.1%. The capital increase with a transaction volume of CHF 122.5 million met with great interest and was significantly oversubscribed. The new shares are eligible for the dividend payment of 06 July 2022. Zürcher Kantonalbank is the Sole Global Coordinator of this capital increase.